Association of NQO1Pro187Ser Polymorphism with Clinical Outcomes and Survival of Lung Cancer Patients Treated with Platinum Chemotherapy

References

• Bray F , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• de Groot PM , WuCC , CarterBW , MundenRF. The epidemiology of lung cancer. Transl. Lung Cancer Res.7(3), 220 (2018).
   PubMed Web of Science ®Google Scholar
• Wu JC , LaiCS , TsaiML , HoCT , WangYJ , PanMH. Chemopreventive effect of natural dietary compounds on xenobiotic-induced toxicity. J. Food Drug Anal.25(1), 176–186 (2017).
   PubMed Web of Science ®Google Scholar
• Jancova P , AnzenbacherP , AnzenbacherovaE. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.154(2), 103–116 (2010).
   PubMed Web of Science ®Google Scholar
• Mandal RK , NissarK , MittalRD. Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India. Mol. Biol. Rep.39(12), 11145–11152 (2012).
   PubMed Web of Science ®Google Scholar
• Yadav U , KumarP , RaiV. NQO1 Gene C609T polymorphism (dbSNP: rs1800566) and digestive tract cancer risk: a meta-analysis. Nutr. Cancer70(4), 557–568 (2018).
   PubMed Web of Science ®Google Scholar
• Pey AL , MegarityCF , TimsonDJ. NAD (P) H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places. Bioscience Rep.39(1), 1–13 (2019).
   Google Scholar
• Jayanthi MK , PrathimaC , RaoMS. NQO1, role in lung cancer: a review. J. Pharm. Sci. Res.7(6), 319–323 (2015).
   Google Scholar
• Malec V , GottschaldOR , LiS , RoseF , SeegerW , HänzeJ. HIF-1α signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radical Bio. Med.48(12), 1626–1635 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang K , ChenD , MaK , WuX , HaoH , JiangS. NAD (P) H: quinone oxidoreductase 1 (NQO1) as a therapeutic and diagnostic target in cancer. J. Med. Chem.61(16), 6983–7003 (2018).
   PubMed Web of Science ®Google Scholar
• den Braver-Sewradj SP , den BraverMW , ToornemanRMet al. Reduction and scavenging of chemically reactive drug metabolites by NAD (P) H: quinone oxidoreductase 1 and NRH: quinone oxidoreductase 2 and variability in hepatic concentrations. Chem. Res. Toxicol.31(2), 116–126 (2018).
   PubMed Web of Science ®Google Scholar
• Tian G , WangM , XuX. The role of NQO1 polymorphisms in the susceptibility and chemotherapy response of Chinese NSCLC patients. Cell Biochem. Biophys.69(3), 475–479 (2014).
   PubMed Web of Science ®Google Scholar
• Masroor M , JainA , JavidJet al. Clinical significance of the NQO1 C609T polymorphism in non-small-cell lung adenocarcinoma patients. Asian Pac. J. Cancer P.16(17), 7653–7658 (2015).
   PubMedGoogle Scholar
• Siegel D , AnwarA , WinskiSL , KepaJK , ZolmanKL , RossD. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD (P) H: quinone oxidoreductase 1. Mol. Pharmacol.59(2), 263–268 (2001).
   PubMed Web of Science ®Google Scholar
• Eom SY , ZhangYW , KimSHet al. Influence of NQO1, ALDH2, and CYP2E1 genetic polymorphisms, smoking, and alcohol drinking on the risk of lung cancer in Koreans. Cancer Cause Control20(2), 137–145 (2009).
   PubMed Web of Science ®Google Scholar
• Kim JH , HongYC. Interactive effect of smoking and NQO1 haplotypes on lung cancer risk. J. Korean Med. Sci.30(3), 221–226 (2015).
   PubMed Web of Science ®Google Scholar
• Lou Y , LiR , XiongLet al. NAD (P) H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis. Tumor Biol.34(6), 3967–3979 (2013).
   PubMedGoogle Scholar
• Huang J , LinH , WuX , JinW , ZhangZ. NQO1 C609T polymorphism and lung cancer susceptibility: evidence from a comprehensive meta-analysis. Oncotarget8(60), 102301 (2017).
   PubMedGoogle Scholar
• Kolesar JM , DahlbergSE , MarshSet al. The NQO1* 2/* 2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small-cell lung cancer. Oncol. Rep.25(6), 1765–1772 (2011).
   PubMed Web of Science ®Google Scholar
• Cui X , JinT , WangX , JinG , LiZ , LinL. NAD (P) H: quinone oxidoreductase-1 overexpression predicts poor prognosis in small-cell lung cancer. Oncol. Rep.32(6), 2589–2595 (2014).
   PubMed Web of Science ®Google Scholar
• Li Z , ZhangY , JinTet al. NQO1 protein expression predicts poor prognosis of non-small-cell lung cancers. BMC Cancer15(1), 207 (2015).
   PubMedGoogle Scholar
• Yang Y , ZhangY , WuQet al. Clinical implications of high NQO1 expression in breast cancers. J. Exp. Clin. Cancer Res.33(1), 14 (2014).
   PubMedGoogle Scholar
• Hou L , LinL. NQO1 overexpression is associated with poor prognosis in the uterine cervix carcinoma. Pract. Oncol. J.30(4), 351–355 (2016).
   Google Scholar
• Ji M , JinA , SunJet al. Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Oncol. Lett.13(5), 2996–3002 (2017).
   PubMed Web of Science ®Google Scholar
• Song SY , JeongSY , ParkHJet al. Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small-cell lung cancer. Lung Cancer68(2), 278–282 (2010).
   PubMed Web of Science ®Google Scholar
• Sunaga N , KohnoT , YanagitaniNet al. Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidem. Prev. Biomarkers11(8), 730–738 (2002).
   PubMed Web of Science ®Google Scholar
• Lin P , HsuehYM , KoJL , LiangYF , TsaiKJ , ChenCY. Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer40(2), 123–129 (2003).
   PubMed Web of Science ®Google Scholar
• Tong YH , ZhangB , YanYYet al. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small-cell lung cancer. Oncotarget8(28), 45750–45758 (2017).
   PubMedGoogle Scholar
• Bahl C , SharmaS , SinghN , BeheraD. Association study between genetic variations in Axin2 gene and lung cancer risk in North Indian population: a multiple interaction analysis. Tumor Biol.39(4), 1–18 (2017).
   Google Scholar
• Saldivar SJ , WangY , ZhaoHet al. An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat. Res.582(1-2), 71–78 (2005).
   PubMed Web of Science ®Google Scholar
• Mei-Miao C , Ying-JuK , Ann-PingT , Gar-YangC , ChauYP. Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma. Histol. Histopathol.24, 1223–1232 (2009).
   PubMed Web of Science ®Google Scholar
• Timofeeva M , KroppS , SauterWet al. Genetic polymorphisms of MPO, GSTT1, GSTM1, GSTP1, EPHX1 and NQO1 as risk factors of early-onset lung cancer. Int. J. Cancer127(7), 1547–1561 (2010).
   PubMed Web of Science ®Google Scholar
• Guo S , GaoM , LiXet al. Lack of association between NADPH quinone oxidoreductase 1 (NQO1) gene C609T polymorphism and lung cancer: a case–control study and a meta-analysis. PLoS ONE7(10), e479399 (2012).
   Web of Science ®Google Scholar
• Lewis SJ , CherryNM , NivenRM , BarberPV , PoveyAC. Polymorphisms in the NAD (P) H: quinone oxidoreductase gene and small-cell lung cancer risk in a UK population. Lung Cancer34(2), 177–183 (2001).
   PubMed Web of Science ®Google Scholar
• Bock CH , WenzlaffAS , CoteML , LandSJ , SchwartzAG. NQO1 T allele associated with decreased risk of later age at diagnosis lung cancer among never smokers: results from a population-based study. Carcinogenesis26(2), 381–386 (2005).
   PubMed Web of Science ®Google Scholar
• Chao C , ZhangZF , BerthillerJ , BoffettaP , HashibeM. NAD (P) H: quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidem. Prev. Biomarkers15(5), 979–987 (2006).
   PubMed Web of Science ®Google Scholar
• Yang M , ChoiY , HwangboB , LeeJS. Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer57(2), 135–142 (2007).
   PubMed Web of Science ®Google Scholar
• Wang YH , LeeYH , TsengPT , ShenCH , ChiouHY. Human NAD (P) H: quinone oxidoreductase 1 (NQO1) and sulfotransferase1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J. Cancer Res. Clin.134(2), 203–209 (2008).
   PubMed Web of Science ®Google Scholar
• Sameer AS , ShahZA , SyeedN , RasoolR , AfrozeD , SiddiqiMA. NAD (P) H: quinone oxidoreductase 1 (NQO1) pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. Asian Pac. J. Cancer P.11(1), 209–213 (2010).
   PubMedGoogle Scholar
• Yuan W , XuL , ChenWet al. Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res. Tr.125(2), 467–472 (2011).
   PubMed Web of Science ®Google Scholar
• Lajin B , AlachkarA. The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis. Brit. J. Cancer109(5), 1325–1337 (2013).
   PubMed Web of Science ®Google Scholar
• Nunobiki O , UedaM , AkiseHet al. GSTM1, GSTT1, and NQO1 polymorphisms in cervical carcinogenesis. Hum. Cell28(3), 109–113 (2015).
   PubMed Web of Science ®Google Scholar
• Lin L , QinY , JinTet al. Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. Exp. Mol. Pathol.96(2), 200–205 (2014).
   PubMed Web of Science ®Google Scholar
• Cui X , LiL , YanGet al. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. BMC Cancer15(1), 244 (2015).
   PubMedGoogle Scholar
• Beaver SK , Mesa-TorresN , PeyAL , TimsonDJ. NQO1: a target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms. Biochim. Biophys. Acta Proteins Proteom.1867(7-8), 663–676 (2019).
   PubMed Web of Science ®Google Scholar